[This Week's IPO] November Fourth Week Demand Forecast and Subscription Schedule

In the fourth week of this month (November), Asterasys, Vect, M&C Solution, Oncocross, and Onconic Therapeutics will conduct demand forecasting targeting institutional investors.

◆Asterasys= Founded in 2015, Asterasys is engaged in the manufacturing and sales of medical devices and beauty equipment. Based on R&D capabilities that combine bio and IT expertise, the company has developed innovative products that lead market trends.

A total of 3.65 million shares will be offered. The desired public offering price per share is 4,000 to 4,600 KRW, with a total expected offering amount of approximately 14.6 billion to 16.8 billion KRW. Demand forecasting will be conducted over five days from the 25th to the 29th, followed by a general subscription on December 4th and 5th, aiming for a listing in December. The lead underwriter is DB Financial Investment.

◆Vect= Established in 2006, Vect is a total visual solution company that provides one-stop services from planning digital content projects for various purposes to hardware production and installation, system operation, and after-sales management, based on advanced digital signage hardware and software capabilities.

The total number of shares offered is 4.75 million, with a desired offering price band of 3,500 to 3,900 KRW, and the offering size is expected to be approximately 16.6 billion to 18.5 billion KRW. The demand forecasting for institutional investors, where the final offering price will be determined, will be conducted over five business days from the 25th to the 29th, and the subscription for general investors will take place on December 4th and 5th. The lead underwriter is Shinhan Investment Corp.

◆M&C Solution= Since its establishment in 1974 and designation as a defense industry company in 1976, M&C Solution has contributed to the development of South Korea's defense industry for over 50 years. The company has continuously developed based on the best driving and precision control technologies that meet customer demands, and to focus its capabilities on the rapidly growing defense business, it split its business division in December 2023 and changed its name from Motrol to M&C Solution.

This IPO will offer 3 million shares. The expected offering price is 80,000 to 93,300 KRW per share, with a total offering amount of 240 billion to 280 billion KRW. Demand forecasting will be conducted over five days from the 26th to December 2nd, followed by a general subscription on December 5th and 6th, aiming for a listing on the KOSPI market within the year. The lead underwriter is KB Securities.

◆Oncocross= Oncocross analyzes drugs in clinical stages through its self-developed AI platform ‘RAPTOR AI’. RAPTOR AI is an AI drug development platform that screens optimal indications for new drug candidates or existing developed drugs.

This IPO will offer 1.423 million shares. The desired public offering price per share is 10,600 to 12,900 KRW, with a total expected offering amount of approximately 15.1 billion to 18.4 billion KRW. Demand forecasting for institutions will be conducted over five days from the 27th to December 3rd, followed by a general subscription on December 9th and 10th, aiming for a December listing. The lead underwriter is Mirae Asset Securities.

◆Onconic Therapeutics= Onconic Therapeutics launched sales of ‘Jacubojeong’, the 37th domestic new drug P-CAB (potassium-competitive acid blocker) expected to replace existing PPIs (proton pump inhibitors) in the peptic ulcer drug market, starting from the 1st of this month.

A total of 1.55 million shares will be offered. The desired offering price per share is 16,000 to 18,000 KRW. Demand forecasting will be conducted from the 27th to December 3rd, followed by a general subscription on December 9th and 10th, aiming for a KOSDAQ listing within the year. The lead underwriter is NH Investment & Securities.